Pipeline and Commercial Perspectives: Psoriasis and Atopic Dermatitis - Reimbursement the key as biologics and TIMs transform disease markets : Market Research Report Reimbursement is the key issue governing the success of biologics for the treatment of psoriasis. The percentage of US patients successfully completing the reimbursement approval process and starting therapy, and the length of time this takes, are key performance metrics used by Biogen and other market players. Early data show that 20% of patients are denied Amevive due to reimbursement status. Datamonitor recommends that developers and marketers of biologics learn from the experiences of Amevive in its immediate post-launch period and commit considerable resources to securing reimbursement of their products for patients in the US. 5 {1} And {2} Partner To Expand Availability Of Protopic - News, Search Jobs, Events News | News By Subject | News by Disease | News By Date | Search News DEERFIELD, Ill., Jan. 26 /PRNewswire/ -- Fujisawa Healthcare, Inc. and Roche International, Ltd. (Roche) announced today that they have entered into an exclusive partnership agreement to expand the global presence of Protopic(R) (tacrolimus ointment), a topical ointment for the treatment of eczema. Under the agreement Roche will be responsible for the exclusive distribution and promotion of Protopic in Mexico, Brazil, Chile, Colombia, Ecuador, Peru, Venezuela, Central America, and the Caribbean.
